Integra LifeSciences

WOUND CARE LEADER, GENTELL, EXPANDS ITS GLOBAL FOOTPRINT ADDING KEY EXECUTIVE LEADERSHIP IN THE UK, EUROPE AND BRAZIL

Retrieved on: 
Monday, January 15, 2024

The new executives include:

Key Points: 
  • The new executives include:
    Our vision: a new paradigm for wound care, using technology, data collection & AI to improve upon delivery & recovery.
  • Singh has been a top executive in the U.K.'s National Health Service (NHS) for nearly 20 years, in both regulation and provider land.
  • Mr. Singh will now lead Gentell U.K. and Europe in its efforts to improve and support patient -specific delivery of affordable wound care treatments.
  • Gentell will manufacture advanced wound care products and dressings at these facilities, as well as in its plant in Pennsylvania.

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Retrieved on: 
Wednesday, January 3, 2024

TEL AVIV, Israel and MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America. Mr. Ligotti brings more than 30 years of general management and commercial leadership experience to the InspireMD team.

Key Points: 
  • TEL AVIV, Israel and MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America.
  • Mr. Ligotti brings more than 30 years of general management and commercial leadership experience to the InspireMD team.
  • Before that, he served as Vice President of Global Commercial Strategy at Smith+Nephew, and, prior to that, in various roles of increasing responsibility at Integra LifeSciences, culminating with Senior Vice President and General Manager - Extremity Orthopedics.
  • In connection with the appointment of Mr. Ligotti as Executive Vice President and General Manager of North America, InspireMD has granted Mr. Ligotti 138,460 shares of restricted stock and stock options to purchase 46,150 shares of InspireMD’s common stock.

Integra LifeSciences Announces Definitive Agreement to Acquire Acclarent®

Retrieved on: 
Wednesday, December 13, 2023

Acclarent is an innovator and market leader in ENT procedures and upon closing, Integra will be one of the leading providers of ENT products and technologies.

Key Points: 
  • Acclarent is an innovator and market leader in ENT procedures and upon closing, Integra will be one of the leading providers of ENT products and technologies.
  • “This acquisition presents Integra with a rare opportunity to become a key player in the ENT segment.
  • Acclarent’s culture of pioneering technologies aligns with Integra’s legacy of innovation to transform care and restore patients’ lives,” said Jan De Witte, president and chief executive officer of Integra LifeSciences.
  • Goldman, Sachs & Co. is serving as exclusive financial advisor and Morgan, Lewis & Bockius LLP is acting as legal advisor to Integra.

Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer

Retrieved on: 
Thursday, November 16, 2023

Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).

Key Points: 
  • Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).
  • View the full release here: https://www.businesswire.com/news/home/20231115733368/en/
    Erik van den Berg, CEO of Memo Therapeutics AG (Photo: Business Wire)
    Mr. van den Berg joins MTx with over 25 years’ industry experience and proven track record in leading and growing companies.
  • Previously, Mr. van den Berg also held business development roles at Organon and IsoTis (sold to Integra Lifesciences).
  • Mr. van den Berg holds a master’s degree in chemistry from the University of Utrecht and an MBA from Manchester Business School.

Integra LifeSciences Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, October 25, 2023

PRINCETON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2023.

Key Points: 
  • PRINCETON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2023.
  • The Company reported GAAP gross margin of 57.1%, compared to 61.5% in the third quarter of 2022.
  • Adjusted EBITDA for the third quarter of 2023 was $88.1 million, or 23.0% of revenue, compared to $105.3 million, or 27.3% of revenue, in the prior year.
  • ET on Wednesday, October 25, 2023, to discuss third quarter 2023 financial results and forward-looking financial guidance.

The 12th Annual Breast Reconstruction Awareness Day returns Oct. 18, 2023 to Increase Recognition of Options with Education, Events and Fundraisers

Retrieved on: 
Thursday, October 19, 2023

ARLINGTON HEIGHTS, Ill., Oct. 19, 2023 /PRNewswire-PRWeb/ -- The American Society of Plastic Surgeons (ASPS) in collaboration with The Plastic Surgery Foundation is pleased to announce the 12th annual Breast Reconstruction Awareness Day known as BRA Day on Oct. 18, 2023.

Key Points: 
  • ARLINGTON HEIGHTS, Ill., Oct. 19, 2023 /PRNewswire-PRWeb/ -- The American Society of Plastic Surgeons (ASPS) in collaboration with The Plastic Surgery Foundation is pleased to announce the 12th annual Breast Reconstruction Awareness Day known as BRA Day on Oct. 18, 2023.
  • Many patients who undergo a mastectomy or lumpectomy because of breast cancer or other health-related conditions are not always aware of all the reconstruction options available to them.
  • Understanding their options for breast reconstruction is critical to making informed decisions about their care and fully healing.
  • ASPS and The PSF launched the Breast Reconstruction Awareness Campaign and the annual BRA Day in 2011.

ValGenesis Presents Impressive Series of Innovations at ValConnect 2023, its Annual User Conference

Retrieved on: 
Tuesday, October 17, 2023

CLEARWATER, Fla., Oct. 17, 2023 /PRNewswire/ -- ValGenesis successfully concluded its annual user conference on Thursday, September 28th, having presented an impressive series of product innovations for 2024 to customers, partners, and industry experts.

Key Points: 
  • CLEARWATER, Fla., Oct. 17, 2023 /PRNewswire/ -- ValGenesis successfully concluded its annual user conference on Thursday, September 28th, having presented an impressive series of product innovations for 2024 to customers, partners, and industry experts.
  • ValGenesis' Vice President of Product Management, Kevin Shaw, kicked off this year's conference with an overview of 2023 and product roadmap for 2024.
  • "ValGenesis will converge them in a new 'Smart Validation' platform, the industry's only unified platform for manufacturing intelligence.
  • ValConnect is an essential conduit for the company's stakeholders to interact, helping them connect, trade ideas, and learn from one another.

Veterinary Electrosurgery Market worth $120 million | MarketsandMarkets

Retrieved on: 
Tuesday, October 10, 2023

In April 2021, DRE Veterinary (US) partnered with Avante Health Solutions (US).

Key Points: 
  • In April 2021, DRE Veterinary (US) partnered with Avante Health Solutions (US).
  • Minimally Invasive: Electrosurgery is often minimally invasive, resulting in smaller incisions, less pain, and reduced scarring for animals post-surgery.
  • Versatility: Electrosurgical instruments can be adapted for various veterinary procedures, including soft tissue surgeries, dermatological treatments, and ophthalmic surgeries, making them versatile tools in veterinary medicine.
  • Enhanced Patient Outcomes: Overall, the advantages of electrosurgery contribute to improved patient outcomes, making it a valuable tool for modern veterinary practices and promoting the well-being of animals.

Veterinary Electrosurgery Market worth $120 million | MarketsandMarkets

Retrieved on: 
Tuesday, October 10, 2023

In April 2021, DRE Veterinary (US) partnered with Avante Health Solutions (US).

Key Points: 
  • In April 2021, DRE Veterinary (US) partnered with Avante Health Solutions (US).
  • Minimally Invasive: Electrosurgery is often minimally invasive, resulting in smaller incisions, less pain, and reduced scarring for animals post-surgery.
  • Versatility: Electrosurgical instruments can be adapted for various veterinary procedures, including soft tissue surgeries, dermatological treatments, and ophthalmic surgeries, making them versatile tools in veterinary medicine.
  • Enhanced Patient Outcomes: Overall, the advantages of electrosurgery contribute to improved patient outcomes, making it a valuable tool for modern veterinary practices and promoting the well-being of animals.

Perimeter Medical Imaging AI Strengthens Leadership Team with Appointment of Experienced MedTech Executive, Adam Hodges, as Vice President, Sales and Marketing

Retrieved on: 
Friday, September 8, 2023

TORONTO and DALLAS, Sept. 8, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, Sales and Marketing, effective immediately.

Key Points: 
  • TORONTO and DALLAS, Sept. 8, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, Sales and Marketing, effective immediately.
  • Adrian Mendes, Perimeter's Chief Executive Officer stated, "I am excited to welcome Adam to the Perimeter team as our senior leader responsible for the strategy and execution of our sales-related goals.
  • Adam Hodges brings more than 20 years of commercialization experience in the medical device industry.
  • Earlier in his career, Adam was an Executive Surgical Device Specialist for United States Surgical (Covidien/Medtronic) and a Sales Representative for Johnson & Johnson.